CAHCardinal Health, Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Jason M. Hollar

Location

Ohio, USA

Exchange

NYSE

Website

https://cardinalhealth.com

Summary

Cardinal Health, Inc.

Company Info

CEO

Jason M. Hollar

Location

Ohio, USA

Exchange

NYSE

Website

https://cardinalhealth.com

Summary

Cardinal Health, Inc.

AI Insights for CAH
5 min read

Quick Summary

Cardinal Health, Inc. is a U.S.-based healthcare services and products company headquartered in Dublin, Ohio. The company operates mainly through its Pharmaceutical and Medical segments, serving hospitals, pharmacies, ambulatory surgery centers, physician practices, laboratories, health systems, and other healthcare providers. Its Pharmaceutical segment distributes branded drugs, generic drugs, specialty pharmaceuticals, over-the-counter healthcare products, and consumer health products. Its Medical segment manufactures, sources, and distributes Cardinal Health-branded medical, surgical, and laboratory products and devices. The company’s main customers are large healthcare institutions, retail and independent pharmacies, specialty-care providers, and organizations that rely on large-scale pharmaceutical and medical supply distribution.

Strengths

•

Cardinal Health’s primary strength is its large scale in healthcare distribution, supported by annual operating revenue of more than $254 billion in the provided data.

•

The company has deep relationships with pharmacies, hospitals, health systems, specialty providers, and manufacturers, which gives it a strong position in the healthcare supply chain.

•

Its Pharmaceutical segment benefits from demand for branded, generic, specialty, and over-the-counter products, while its Medical segment adds diversification through surgical, laboratory, and medical supply distribution.

•

The company’s low beta and defensive healthcare exposure may appeal to investors seeking stability in uncertain markets.

•

Cardinal Health also has a dividend history, a five-year dividend streak in the provided data, and a strategic push into higher-value specialty-care services.

Key Risks

•

Cardinal Health faces significant risks from customer concentration, contract losses, and pricing pressure in pharmaceutical distribution.

•

The loss of OptumRx contracts has already affected revenue, and future losses of large customers could create additional pressure.

•

Regulatory risks are also important because drug distribution, pharmacy services, controlled substances, reimbursement, and healthcare transactions are closely monitored by government agencies.

•

Supply constraints, labor costs, inflation, and logistics disruptions could hurt service levels or margins.

What to Watch

During the most recent reported period, Cardinal Health continued to report strong performance in branded and specialty pharmaceuticals.
The company also benefited from improved margins and progress in its generics program, which helped support earnings despite revenue headwinds from customer contract losses.
A major event was the announcement that Cardinal Health would acquire a 75% stake in Solaris Health for $1.9 billion, valuing the urology management services organization at about $2.4 billion.
This transaction is expected to expand Cardinal Health’s Specialty Alliance to around 3,000 providers across 32 states and deepen its exposure to urology.
The quarter was also shaped by continued attention to prior acquisitions such as ION and Specialty Networks, which support oncology and specialty services expansion.

Price Drivers

•

Cardinal Health’s stock price is being driven by strong growth in branded and specialty pharmaceuticals, improved margins, and investor confidence in its turnaround execution.

•

The company’s valuation reflects a high price-to-earnings ratio of about 34.5 based on the provided data, while its earnings yield of roughly 2.9% suggests investors are pricing in continued operating progress.

•

Its low beta of 0.501 indicates the stock may be viewed as relatively defensive compared with the broader market, which can attract investors during uncertain macroeconomic periods.

•

Recent acquisitions and specialty-care expansion, including the planned Solaris Health investment, are also important price drivers because they signal a move into higher-growth healthcare services.

•

Offsetting factors include the loss of OptumRx contracts, supply constraints, regulatory exposure, and intense competition from McKesson and Cencora.

Recent News

•

Recent news highlights Cardinal Health’s agreement to acquire a 75% stake in Solaris Health for $1.9 billion.

•

The deal values Solaris Health at about $2.4 billion and expands Cardinal Health’s Specialty Alliance to roughly 3,000 providers across 32 states.

•

The transaction strengthens Cardinal Health’s focus on urology and is expected to slightly increase EPS.

•

Other recent commentary notes strong growth in branded and specialty pharmaceuticals, improved margins, and benefits from the company’s generics program.

•

News coverage also points to ongoing risks, including the revenue impact from lost OptumRx contracts, supply constraints, competition, and regulatory challenges.

Market Trends

•

Cardinal Health is affected by broader healthcare trends such as rising specialty drug demand, growth in biologics, expansion of outpatient care, and increased need for efficient healthcare logistics.

•

The global pharmacy industry is projected to grow significantly, supported by AI, automation, outsourcing, partnerships, and greater healthcare utilization.

•

Healthcare logistics is also expected to expand, driven by pharma distribution, cold-chain requirements, home healthcare, smart inventory, and last-mile delivery.

•

Medical distributors such as Cardinal Health, McKesson, and Cencora have recently performed well because scale, execution, and specialty-drug exposure are increasingly valued by investors.

•

At the same time, inflation, labor shortages, supply-chain pressure, regulation, generic drug pricing weakness, and intense competition remain important industry headwinds.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on CAH

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@Theta_collctv 9 months ago

Logistics stocks drop as former karaoke company sparks AI fears

Logistics stocks drop as former karaoke company sparks AI fears

post thumbnail
avatar
@BarnaclesActiv 9 months ago

Overview of healthcare sector opportunities and recent stock picks

Overview of healthcare sector opportunities and recent stock picks

post thumbnail
avatar
@BrianHoward 10 months ago

Cardinal Health is looking strong

Cardinal Health is looking strong

I noticed Cardinal Health is picking up some serious momentum today after those price target upgrades. It seems like analysts are really backing the long-term growth for through 2026. What do you all think about the pharmaceutical distribution space right now?

avatar
@Altruistic_Dr2 11 months ago

Quick recap of Q3 earnings: Retailers popping, mixed bag for tech

Quick recap of Q3 earnings: Retailers popping, mixed bag for tech

post thumbnail
avatar
@kewur 1 year ago

S&P 500 Q3 earnings show strong growth, retail and tech in focus

S&P 500 Q3 earnings show strong growth, retail and tech in focus

post thumbnail

No more topics to show